Discussion on Quality Control Requirements for Activated Carbon in Pharmaceutical Applications

In pharmaceutical production, activated carbon, as a classic and highly efficient pharmaceutical excipient, is known as a "sponge in liquids". It plays a key role in adsorbing impurities, improving purity and ensuring drug safety, whether in the refining of active pharmaceutical ingredients or the pyrogen control of injections and oral solutions.

However, due to its strong adsorption capacity, activated carbon itself may become a source of contamination if quality control is not in place. How to control the quality of activated carbon scientifically and rigorously in the pharmaceutical field is a subject that every pharmaceutical professional must face squarely.

 

 

I. Why is Medicinal Activated Carbon "Different"?

Activated carbon is made from raw materials such as wood chips, nut shells and coal through high-temperature carbonization and activation. In the pharmaceutical field, we focus not only on its specific surface area and adsorption capacity, but also on its safety and cleanliness. 

Different from industrial-grade activated carbon, the core of quality control for medicinal activated carbon lies in:

• Reducing soluble impurities: avoiding the introduction of toxic substances such as heavy metals and arsenic salts.
• Controlling microbial load, with extremely strict limits on endotoxins (pyrogens) for activated carbon for injection.
• Reducing soluble salts: preventing interference with the pH value and osmotic pressure of the liquid medicine.

 

II. Key Indicators of Quality Control

In accordance with the requirements of the Chinese Pharmacopoeia and relevant regulations, the quality control of activated carbon in the pharmaceutical field mainly focuses on the following dimensions:

1. Acidity, Alkalinity and Chlorides

These are the most basic physical and chemical indicators. If activated carbon is not thoroughly washed during production, residual acidic or alkaline substances will change the pH value of the liquid medicine and affect the stability of the drug. The limit control of impurities such as chlorides and sulfates directly reflects the purification process level of activated carbon.

2. Adsorption Capacity

Adsorptive capacity is the core property of activated carbon. Activated carbon adsorption efficiency is usually evaluated by methylene blue adsorption value and quinine sulfate adsorption value, which determine its decolorization and organic impurity removal performance.

It should be noted that: higher adsorption capacity is not always better. In specific pharmaceuticals, excessively strong adsorption capacity may lead to the adsorption of active pharmaceutical ingredients, resulting in a decrease in content. Therefore, when selecting activated carbon, matching tests should be carried out according to the molecular weight and polarity of the specific drug.

3. Heavy Metals and Arsenic Salts

This is the safety red line for medicinal activated carbon. Heavy metals (such as lead, cadmium, mercury) and arsenic have significant toxicity. Pharmacopoeia standards usually stipulate that "heavy metals shall not exceed 30 parts per million (30 ppm)". Enterprise internal control standards are often stricter than pharmacopoeia standards to ensure the safety of long-term medication.

4. Microbial Limit and Bacterial Endotoxins

For sterile preparations such as injections and eye drops, bacterial endotoxins (pyrogens) are the "top priority" in the quality control of activated carbon.

Activated carbon itself has the advantage of adsorbing endotoxins, but if it carries a large number of microorganisms, it may release endotoxins under a moist heat environment, which will instead increase the pyrogen load of the liquid medicine.

Accordingly, activated carbon for injection is generally subjected to bacterial endotoxin testing and must meet the pyrogen-free grade.

 

III. Compliance Considerations in the Application Process

In addition to the quality standards of the raw material itself, the application of activated carbon in pharmaceutical production must also meet the requirements of GMP (Good Manufacturing Practice):

1. Supplier Management and Source Control

Since the pore structure and impurity spectrum of activated carbon are closely related to the source of raw materials, pharmaceutical enterprises should conduct strict on-site audits of suppliers. Focus on the stability of raw material origin, activation process (chemical method vs. physical method) and washing process.

2. Pre-use Treatment

Although finished activated carbon meets pharmacopoeial standards, activation treatment is still commonly performed in actual production. For instance, in injection manufacturing, acid treatment, water washing, or high-temperature baking is used to further remove soluble impurities and volatile substances from the activated carbon surface, preventing "black spots" or "turbidity" and ensuring the stability of activated carbon for injection.

3. Residue Control

• Activated carbon must not remain in drug solutions. An effective decarbonization process (e.g., titanium rod filtration, depth filtration) must be established and validated to completely remove residual activated carbon after activated carbon adsorption.
• Key points: verification contents include the retention effect of activated carbon (clarity of filtrate), filter integrity test, and risk control to prevent visible foreign matter exceeding the standard caused by activated carbon passing through the filter element.

 

 

IV. New Industry Trends and Reflections

With the continuous upgrading of pharmaceutical processes, the application of activated carbon is also facing new challenges and changes:

• Emergence of "carbon-free" processes: In some high-end injections (e.g., liposomes, certain biological preparations), "carbon-free" depyrogenation processes are adopted because activated carbon is difficult to remove completely or may adsorb active ingredients. However, this does not mean activated carbon is obsolete; activated carbon adsorption remains the most cost-effective solution for chemical APIs and traditional preparations.
• Differentiation of internal control standards: more and more enterprises are no longer satisfied with only meeting pharmacopoeia standards, but have established stricter "internal control standards" according to the characteristics of their own products. For example, adsorption verification for specific solvent residues and specific impurities, and even optimization of filtration efficiency through "particle size distribution" control. 

 

V. Conclusion

Although small in size, activated carbon is an important part of drug quality assurance. From raw material screening to incoming inspection, from pre-use treatment to post-use removal, every link reflects the pharmaceutical professionals' practice of the concept of "Quality by Design".

Today, as the pharmaceutical industry moves towards high-quality development, we should not only give play to the adsorption advantages of activated carbon, but also avoid its potential risks through a scientific quality control system. Only in this way can the purity and safety of each batch of drugs be ensured. 

 

If you need samples of Medicinal Activated Carbon that meet pharmacopoeia standards, technical support, or customized quality control plans, please leave your inquiry. We will provide you with a one-on-one response. 

Contact now